291275-45-1

Basic information

• Product Name: (Z)-tert-butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane
• Synonyms: (Z)-tert-butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane
• CAS NO: 291275-45-1
• Molecular Weight: 282.886
• Mol File: 291275-45-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (Z)-tert-butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-tert-butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane(291275-45-1)
• EPA Substance Registry System: (Z)-tert-butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane(291275-45-1)

Safety Data

• Hazardous Substances Data: 291275-45-1(Hazardous Substances Data)

Upstream product

• 34841-35-5 3'-chloro-propiophenone 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 1190391-42-4 tert-butyldimethyl(1-m-chlorophenyl-prop-2-en-1-yloxy)silane 
• 587-04-2 m-Chlorobenzaldehyde 

Downstream Products

• 287477-53-6 (S)-1-(3-chlorophenyl)-2-hydroxypropan-1-one 
• 291275-46-2 (R)-(+)-1-(3-chlorophenyl)-2-hydroxypropan-1-one 
• 192374-14-4 radafaxine 
• 192374-15-5 (R,R)-Hydroxybupropion 
• 291275-48-4 Trifluoro-methanesulfonic acid (R)-2-(3-chloro-phenyl)-1-methyl-2-oxo-ethyl ester 
• 291275-47-3 Trifluoro-methanesulfonic acid (S)-2-(3-chloro-phenyl)-1-methyl-2-oxo-ethyl ester 
• 1231951-92-0 (2S,3S)-2-(3-chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol 

Relevant articles and documents

Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate

A stereospecific method for the synthesis of enantiopure α-aminoketone from its corresponding α-hydroxy-ketone via the triflate intermediate is discussed. This strategy provides a rapid and efficient route for the preparation of either enantiomer of bupro

HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE

The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.